Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.
|Articles|September 16, 2013
World Sight Day Challenge Coalition supports OGS
Organizations and manufacturers in vision care have joined together to promote expand access to eye care through the World Sight Day Challenge.
Advertisement
Rancho Cordova, CA-Organizations in the eyecare industry have formed the World Sight Day Challenge Coalition to help raise awareness and mobilize support behind eye health and eye care, leading up to
Coalition members include :
- ABB Optical Group
- Alcon
- AllAboutVision.com
- CooperVision
- Essilor
- Eyefinity
- Marchon Eyewear
- TLC Laser Eye Centers
- Transitions Optical
- Vistakon Division of Johnson & Johnson Vision Care Inc.
- Vision Source
- VSP Optics Group
- VSP Vision Care
The Coalition’s objective is to promote the importance of eye health, and help expand access to eye care through support of
Advertisement
Related to this article
CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.
Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.
Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.
Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.
From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.
Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for managing near vision loss.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
2
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
3
More than monitoring: Using AMD visits to promote healthy vision aging
4
The Independent Advantage S02 E07: Is your front desk missing opportunities?
5